)

Revolution Medicines (RVMD) investor relations material
Revolution Medicines Study Result summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Disease background and unmet need
Pancreatic ductal adenocarcinoma (PDAC) is highly lethal, with a five-year survival rate of 3% and over 90% of cases harboring RAS driver mutations, making RAS a key therapeutic target.
Most patients are diagnosed at a metastatic stage, where cytotoxic chemotherapy is the global standard but outcomes remain poor.
There is a significant need for improved efficacy and tolerability in both first- and second-line PDAC treatments.
Mechanism and preclinical data
Daraxonrasib (diraxonrasib) is a multi-selective RAS(ON) inhibitor targeting nearly all oncogenic RAS variants, including wildtype.
Preclinical models showed deep, durable monotherapy and combination activity, with improved response when combined with gemcitabine/nab-paclitaxel (GnP/GMP).
Clinical results: second-line PDAC
In second-line PDAC, daraxonrasib monotherapy achieved a 35% ORR in RAS G12X and 29% in all RAS mutant patients, with DCRs of 92–95%, median PFS of 8.1–8.5 months, and median OS of 13.1–15.6 months.
Safety profile was manageable, with 96% experiencing any-grade TRAEs and 34% grade ≥3; dose modifications were required in 48% of patients.
Next Revolution Medicines earnings date

Next Revolution Medicines earnings date

The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
)
)
)
Frequently asked questions
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Explore our global coverage